17 January 2022
HealthBeacon plc
("HealthBeacon" or the "Company")
Issue of Equity
HealthBeacon (Euronext Growth: HBCN), a digital therapeutics company that develops products for managing injectable medications for patients in the home announces that the Company has applied for the admission of 77,579 new ordinary shares of €0.0025 each in the Company (the "Ordinary Shares") pursuant to the 2014 HealthBeacon employee share option plan ("ESOP") as referred to in the Company's Information Document, published on the 10 December 2021.
Application has been made for the new Ordinary Shares to be admitted to trading on Euronext Growth, a market operated by Euronext Dublin and it is expected that admission will take place on 19 January 2022.
Following this admission, the total issued share capital of the Company will increase to 16,889,626 ordinary shares. No further shares are to be admitted pursuant to the ESOP.
Enquiries:
| HealthBeacon Laurence Flavin |
Investor.Relations@HealthBeacon.com |
| Goodbody (Euronext Growth Adviser and Broker):
David Kearney Stephen Kane Chris McAuliffe
|
+353 (1) 667-0420
|
| Drury (Public Relations):
Billy Murphy Cathal Barry
|
+353 (0) 87 231 3085 +353 (0) 87 227 9281 |
Background to the Company
Headquartered in Dublin since being established in 2013, HealthBeacon is an Irish digital therapeutics company that develops products for managing injectable medications for patients in the home. The HealthBeacon injection care management system tracks adherence and persistence with medication schedules through the provision of medication management reminders, safe and sustainable sharps disposal devices, educational tools and AI driven data analytics. The Company operates in 17 markets across Europe, North America and the United Kingdom and employs more than 50 people. HealthBeacon has obtained more than 30 design and utility patents and in 2018 received a Class II Medical Device certificate from the FDA for a sharps bin intended for home use.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.